Company Overview of Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. discovers and develops drugs in the field of epigenetics. The company discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its pipeline includes bromodomain and extra-terminal proteins that regulate gene expression and small molecule inhibition; and EZH2, a histone lysine methyltransferase that works cooperatively as part of a multi-subunit complex known as PRC2. The company also provides target validation tools; biochemical, biophysical, and cell-based assays; and compound collections against targets in each of the writer, eraser, and reader classes. In addition, its discov...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Constellation Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.
Constellation Pharmaceuticals, Inc. Key Developments
Constellation Pharmaceuticals, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 07:30 AM
Jan 6 16
Constellation Pharmaceuticals, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 07:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Keith E. Dionne, Chief Executive Officer, President and Director.
Constellation Pharmaceuticals Mulls IPO
Aug 24 15
Constellation Pharmaceuticals, Inc. is seeking IPO. Keith Dionne, President and Chief Executive Officer of Constellation Pharmaceuticals, said, “Constellation plans to raise a crossover round and hopes to conduct an IPO in first half of 2016.”
Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 1, 2015